Gini Fleming
· Professor of MedicineUniversity of Chicago · Hematology and Blood and Marrow Transplantation
Active 1932–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Gini Fleming, MD, is a Professor of Medicine at the University of Chicago, specializing in medical oncology with a focus on new drug development for advanced breast and gynecologic malignancies, including cervical, ovarian, and endometrial cancers. She directs the GYN medical oncology program and co-directs the Developmental Therapeutics program. Dr. Fleming has a background that includes an MD from the University of Illinois Chicago and a BA in Chemistry from Oberlin College. Her research encompasses validation of cancer risk calculators, clinical trials on genetic testing accessibility, and studies on treatment responses among diverse populations. She serves as the GYN section editor for the Journal of Clinical Oncology and has authored over 200 peer-reviewed publications, contributing significantly to the understanding and treatment of gynecologic and breast cancers.
Research topics
- Oncology
- Medicine
- Internal medicine
- Pathology
- Surgery
- Intensive care medicine
- Nuclear medicine
- Biology
- Radiology
- Bioinformatics
Selected publications
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment
Obstetrics and Gynecology · 2020 · 334 citations
The medical and surgical treatment strategies for women with epithelial ovarian cancer continue to evolve. In the past several years, there has been significant progress backed by landmark clinical trials. Although primary epithelial ovarian cancer is still treated with a combination of surgery and systemic therapy, more complex surgical procedures and novel therapeutics have emerged as standard of care. Cytotoxic chemotherapy and maximal surgical effort remain mainstays, but targeted therapies…
Journal of Clinical Oncology · 2020 · 324 citations
Senior authorCorrespondingPURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: and carboplatin area under the curve 6 (day 1) every 21 days for seven cycles. The primary endpoint was overall survival (OS; modified intention to treat). Progression-free survival (PFS), health-related quality of life…
The Lancet · 2021 · 206 citations
Clinical Cancer Research · 2020 · 70 citations
PURPOSE: Multisite stereotactic body radiotherapy followed by pembrolizumab (SBRT+P) has demonstrated safety in advanced solid tumors (ASTs). However, no studies have examined the relationships between irradiated tumor response, SBRT-induced tumor gene expression, and overall survival (OS). PATIENTS AND METHODS: Patients with AST received SBRT (30-50 Gy in 3-5 fractions) to two to four metastases followed by pembrolizumab (200 mg i.v. every 3 weeks). SBRT was prescribed to a maximum tumor volume…
Clinical Cancer Research · 2021 · 42 citations
PURPOSE: CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab (CSF1R inhibitor). PATIENTS AND METHODS: This phase I clinical trial enrolled patients with advanced solid tumors that had progressed on standard therapies. SBRT was delivered to 1-4 metastases with nivolumab+urelumab or nivolumab+cabiralizumab give…
Recent grants
Alliance for Clinical Trials in Oncology Operations Center - GY11 Funded Extension
NIH · $256.0M · 2014–2026
NIH · $6.7M · 2015
Frequent coauthors
- 488 shared
Prudence A. Francis
University of Melbourne
- 429 shared
Meredith M. Regan
Dana-Farber Cancer Institute
- 422 shared
Carol Aghajanian
- 416 shared
Michael J. Birrer
Winthrop Rockefeller Foundation
- 408 shared
Michael A. Bookman
Kaiser Permanente
- 392 shared
Karen N. Price
- 375 shared
István Láng
- 351 shared
Kathleen N. Moore
University of Oklahoma Health Sciences Center
Education
- 1985
M.D., Medicine
University of Illinois
- 1981
B.A., Chemistry
Oberlin
Similar researchers at University of Chicago
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Gini Fleming
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup